Metastatic breast cancer trials in Austria

In Austria 11 Also abroad 610

11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Feldkirch, Graz, Linz, Vienna
Age
18 years and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
Phase 2/3Taking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Graz, Linz, Salzburg, Vienna
Age
18 years and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
Phase 3Taking people
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
Where
Innsbruck, Linz, Vienna, Wels
Age
18 years and over
People
264 worldwide
Run by
Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00
Phase 3Taking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Graz, Innsbruck, Linz, Vienna
Age
18 years and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
Phase 2Taking people
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Where
Innsbruck
Age
18 years and over
People
60 worldwide
Run by
Abscint NV/SA
See details and how to joinNCT06369831 · EU 2024-511419-22-00
Phase 3Taking people
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Where
Krems An Der Donau, Linz, Salzburg, Vienna, Wels
Age
18 years and over
People
1,000 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00
Phase 3Taking people
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Where
Innsbruck, Linz, Schwaz, Vienna
Age
18 years and over
People
300 worldwide
Run by
MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00
No phaseTaking people
DESTINY Breast Respond HER2-(Ultra)Low Europe
Where
Graz, Innsbruck, Klagenfurt, Leoben, Linz, Rankweil, Salzburg, Vienna, Vöcklabruck, Wels, Wiener Neustadt
Age
18 years and over
People
2,295 worldwide
Run by
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732
Phase 2Taking people
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Where
Graz, Linz, Vienna
Age
18 years and over
People
200 worldwide
Run by
MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00
Phase 2Taking people
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Where
Graz, Vienna
Age
18 years and over
People
37 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00
No phaseTaking people
Metastatic Breast Cancer in Austria
Where
Braunau am Inn, Dornbirn, Feldkirch, Graz, Innsbruck, Kufstein, Leoben, Linz, Salzburg, Sankt Pölten, Steyr, Vienna, Wels
Age
18 years and over
People
5,000
Run by
Arbeitsgemeinschaft medikamentoese Tumortherapie
See details and how to joinNCT03870620